- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1432-0428
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Diabetes, bone and glucose-lowering agents: basic biology ; volume:60 ; number:7 ; day:22 ; month:4 ; year:2017 ; pages:1163-1169 ; date:7.2017
Diabetologia ; 60, Heft 7 (22.4.2017), 1163-1169, 7.2017
- Keyword
-
Endokrinologie
- Creator
-
Lecka-Czernik, Beata
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s00125-017-4269-4
- URN
-
urn:nbn:de:1111-201706245176
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:23 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Lecka-Czernik, Beata
- SpringerLink (Online service)
Other Objects (12)
Selective amyloid-β lowering agents
Pharmacogenetics of novel glucose-lowering drugs
SGLT2i: beyond the glucose-lowering effect
Basic biology
Critical Appraisal of Amyloid Lowering Agents in AD
Chronic Medication Burden and Complexity for US Patients with Type 2 Diabetes Treated with Glucose-Lowering Agents
How Do the Recent Major Randomized Controlled Trials Inform Best Use of the Novel Glucose-Lowering Agents?
Dyslipidemia, lipid-lowering agents and neuroendocrine neoplasms: new horizons
Time to Failure on Oral Glucose-Lowering Agents for Patients with Type 2 Diabetes: A Retrospective Cohort Study
Cardiovascular outcome trials of glucose-lowering medications: an update
From glucose lowering agents to disease/diabetes modifying drugs: a “SIMPLE” approach for the treatment of type 2 diabetes
Basic techniques in molecular biology
Selective amyloid-β lowering agents
Pharmacogenetics of novel glucose-lowering drugs
SGLT2i: beyond the glucose-lowering effect
Basic biology
Critical Appraisal of Amyloid Lowering Agents in AD
Chronic Medication Burden and Complexity for US Patients with Type 2 Diabetes Treated with Glucose-Lowering Agents
How Do the Recent Major Randomized Controlled Trials Inform Best Use of the Novel Glucose-Lowering Agents?
Dyslipidemia, lipid-lowering agents and neuroendocrine neoplasms: new horizons
Time to Failure on Oral Glucose-Lowering Agents for Patients with Type 2 Diabetes: A Retrospective Cohort Study
Cardiovascular outcome trials of glucose-lowering medications: an update
From glucose lowering agents to disease/diabetes modifying drugs: a “SIMPLE” approach for the treatment of type 2 diabetes
Basic techniques in molecular biology
Selective amyloid-β lowering agents
Pharmacogenetics of novel glucose-lowering drugs
SGLT2i: beyond the glucose-lowering effect
Basic biology
Critical Appraisal of Amyloid Lowering Agents in AD
Chronic Medication Burden and Complexity for US Patients with Type 2 Diabetes Treated with Glucose-Lowering Agents
How Do the Recent Major Randomized Controlled Trials Inform Best Use of the Novel Glucose-Lowering Agents?
Dyslipidemia, lipid-lowering agents and neuroendocrine neoplasms: new horizons
Time to Failure on Oral Glucose-Lowering Agents for Patients with Type 2 Diabetes: A Retrospective Cohort Study
Cardiovascular outcome trials of glucose-lowering medications: an update
From glucose lowering agents to disease/diabetes modifying drugs: a “SIMPLE” approach for the treatment of type 2 diabetes